GIFT Study: Genetic Testing Viable For Personalizing Antiplatelet Therapy
This article was originally published in The Gray Sheet
Executive SummaryA recent study supports a role for genetic testing as a means of personalizing antiplatelet therapy following stent placement and builds the case that newer drugs, such as Eli Lilly/Daiichi Sankyo's Effient (prasugrel), are more appropriate options for those who have poor response to standard Plavix (clopidogrel) treatment.
You may also be interested in...
Two trials testing Tgen’s approach to using genomics algorithms to help select cancer treatments are ongoing. The further ambition is to unite outcomes data in electronic health records and genomics data to get an even more personalized view of what’s going on with a patient.
Data presented at TCT may support rapid, point-of-care genetic testing in tailoring antiplatelet therapy, but clinicians are still not convinced.
Data presented at the Transcatheter Cardiovascular Therapeutics meeting may support rapid, point-of-care genetic testing in tailoring antiplatelet therapy, but clinicians are still not convinced.